kymera
therapeutics
present
interim
results
study
characterizing
expression
demonstrating
proof
mechanism
degrader
patients
hidradenitis
data
presented
annual
symposium
hidradenitis
suppurativa
advances
shsa
results
support
clinical
development
protein
degrader
hidradenitis
suppurativa
hs
autoimmune
inflammatory
diseases
phase
trial
track
start
watertown
globe
newswire
kymera
therapeutics
nasdaq
kymr
biopharmaceutical
company
advancing
targeted
protein
degradation
deliver
novel
small
molecule
protein
degrader
therapeutics
today
announced
company
present
interim
data
trial
evaluating
expression
skin
blood
patients
hs
atopic
dermatitis
ad
well
effect
lead
degrader
levels
peripheral
blood
mononuclear
cells
pbmc
following
ex
vivo
treatment
data
presented
annual
symposium
hidradenitis
suppurativa
advances
shsa
friday
et
poster
controls
signaling
receptors
receptors
tlr
play
key
roles
pathogenesis
various
autoimmune
inflammatory
diseases
including
hs
painful
debilitating
inflammatory
skin
disease
limited
treatment
options
said
jared
gollob
md
chief
medical
officer
kymera
therapeutics
goal
conducting
study
hs
ad
early
understand
expression
diseased
tissues
demonstrate
ex
vivo
proof
mechanism
lead
degrader
patients
prior
conducting
first
clinical
studies
completed
accrual
hs
patients
interim
data
hs
support
relevance
signaling
pathway
ability
lower
levels
across
pbmc
subsets
thereby
differentiating
pharmacodynamic
effect
kinase
conducted
collaboration
afsaneh
alavi
md
york
dermatology
clinic
research
center
ontario
canada
trial
enrolling
patients
mild
moderate
severe
hs
patients
moderate
severe
ad
levels
expression
proinflammatory
cytokines
measured
skin
biopsies
obtained
lesional
skin
blood
effect
kinase
inhibitor
levels
cytokine
production
measured
following
ex
vivo
incubation
whole
blood
interim
trial
results
expression
skin
blood
hs
patients
impact
levels
hs
pbmc
presented
today
shsa
highly
encouraged
initial
findings
characterize
expression
skin
blood
patients
hs
debilitating
disease
cutaneous
systemic
inflammation
higher
levels
observed
skin
active
lesions
circulating
monocytes
cell
type
plays
key
role
pathogenesis
hs
along
ability
suppress
expression
pbmc
irrespective
baseline
intensity
provide
strong
scientific
rationale
evaluation
degraders
treat
hs
said
alavi
principal
investigator
formerly
york
dermatology
clinic
research
center
currently
mayo
clinic
rochester
mn
look
forward
analyzing
full
trial
results
part
ongoing
efforts
advance
new
therapies
patients
hs
ad
high
unmet
medical
trial
exemplifies
kymera
commitment
working
disease
area
experts
outset
order
understand
target
expression
ex
vivo
pharmacodynamic
activity
degraders
diseased
tissue
indications
intend
develop
said
nello
mainolfi
phd
ceo
kymera
therapeutics
results
date
hs
patients
support
plans
clinical
development
track
initiate
phase
trial
first
half
shsa
poster
presentation
highlights
poster
interim
results
study
evaluate
cutaneous
circulating
biomarkers
novel
therapeutic
patients
hidradenitis
suppurativa
presented
alavi
data
presented
hs
patients
enrolled
showed
expression
quantified
skin
using
immunofluorescence
mass
spectrometry
ms
pbmc
flow
cytometry
expression
skin
higher
lesional
skin
compared
unaffected
skin
detected
blood
across
pbmc
subsets
highest
expression
monocytes
ex
vivo
treatment
whole
blood
degrader
substantially
lowered
levels
across
pbmc
subsets
blood
whereas
ex
vivo
treatment
kinase
inhibitor
increased
levels
nk
cells
kymera
presented
preclinical
data
earlier
year
european
hidradenitis
suppurativa
foundation
scientific
conference
demonstrating
oral
daily
dosing
degraders
completely
suppressed
protein
expression
skin
immune
cells
inhibited
cutaneous
inflammation
preclinical
research
presented
american
college
rheumatology
meeting
last
year
showed
inhibition
vitro
cytokine
chemokine
induction
tlr
agonists
alone
combined
superior
degraders
compared
kinase
inhibitors
select
kymera
posters
presentations
publications
including
today
shsa
presentation
slides
found
link
https
kymera
therapeutics
kymera
therapeutics
biopharmaceutical
company
focused
transformative
new
approach
address
previously
intractable
disease
targets
kymera
advancing
field
targeted
protein
degradation
accessing
body
innate
protein
recycling
machinery
degrade
dysregulated
proteins
kymera
pegasus
targeted
protein
degradation
platform
harnesses
body
natural
protein
recycling
machinery
degrade
proteins
focus
nodes
validated
pathways
currently
inaccessible
conventional
therapeutics
kymera
accelerating
drug
discovery
unmatched
ability
target
degrade
intractable
proteins
advance
new
treatment
options
patients
kymera
initial
programs
target
irakimid
within
tlr
jak
stat
pathways
providing
opportunity
treat
broad
range
diseases
hematologic
malignancies
solid
tumors
information
visit
kymera
therapeutics
proprietary
protein
degradation
platform
created
team
experienced
drug
hunters
improve
effectiveness
targeted
protein
degradation
generate
pipeline
novel
therapeutics
previously
undruggable
diseases
platform
consists
informatics
driven
target
identification
novel
ligases
proprietary
ternary
complex
predictive
modeling
capabilities
degradation
tools
cautionary
note
regarding
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
amended
including
without
limitation
implied
express
statements
regarding
strategy
business
plans
focus
plans
timelines
clinical
development
kymera
therapeutics
product
candidates
therapeutic
potential
clinical
benefits
thereof
growth
company
expectations
regarding
future
interactions
food
drug
administration
fda
uses
capital
words
may
might
could
would
expect
plan
anticipate
intend
believe
expect
estimate
seek
predict
future
project
potential
continue
target
similar
words
expressions
intended
identify
statements
although
statements
contain
identifying
words
statements
press
release
based
management
current
expectations
beliefs
subject
number
risks
uncertainties
important
factors
may
cause
actual
events
results
differ
materially
expressed
implied
statements
contained
press
release
including
without
limitation
risks
associated
impact
countries
regions
operations
business
well
timing
anticipated
results
current
preclinical
studies
future
clinical
trials
strategy
future
operations
delay
current
preclinical
studies
future
clinical
trials
development
kymera
therapeutics
drug
candidates
risk
results
current
preclinical
studies
may
predictive
future
results
connection
future
clinical
trials
kymera
therapeutics
ability
successfully
demonstrate
safety
efficacy
drug
candidates
timing
outcome
company
planned
interactions
regulatory
authorities
obtaining
maintaining
protecting
intellectual
property
risks
uncertainties
described
greater
detail
section
entitled
risk
factors
final
prospectus
dated
august
filed
pursuant
rule
b
securities
amended
securities
exchange
commission
well
discussions
potential
risks
uncertainties
important
factors
kymera
therapeutics
subsequent
filings
securities
exchange
commission
addition
statements
represent
kymera
therapeutics
views
today
relied
upon
representing
views
subsequent
date
kymera
therapeutics
explicitly
disclaims
obligation
update
statements
representations
warranties
expressed
implied
made
accuracy
statements
contact
investors
bruce
jacobs
chief
financial
officer
christopher
brinzey
westwicke
icr
company
kymera
therapeutics
media
lissette
steele
verge
scientific
communications
kymera
therapeutics
lsteele
